Literature DB >> 22648863

Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies.

Douglas D Banks1, Ramil F Latypov, Randal R Ketchem, Jon Woodard, Joanna L Scavezze, Christine C Siska, Vladimir I Razinkov.   

Abstract

In the present report, two formulation strategies, based on different aggregation models, were compared for their ability to quickly predict which excipients (cosolutes) would minimize the aggregation rate of an immunoglobulin G1 monoclonal antibody (mAb-1) stored for long term at refrigerated and room temperatures. The first formulation strategy assumed that a conformational change to an aggregation-prone intermediate state was necessary to initiate the association process and the second formulation strategy assumed that protein self-association was instead controlled by the solubility of the native state. The results of these studies indicate that the stabilizing effect of excipients formulated at isotonic concentrations is derived from their ability to solubilize the native state, not by the increase of protein conformational stability induced by their presence. The degree the excipients solvate the native state was determined from the apparent transfer free energy of the native state from water into each of the excipients. These values for mAb-1 and two additional therapeutic antibodies correlated well to their long-term 4°C and room temperature aggregation data and were calculated using only the literature values for the apparent transfer free energies of the amino acids into the various excipients and the three-dimensional models of the antibodies.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22648863     DOI: 10.1002/jps.23219

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

1.  Isotonic concentrations of excipients control the dimerization rate of a therapeutic immunoglobulin G1 antibody during refrigerated storage based on their rank order of native-state interaction.

Authors:  Douglas D Banks; Jon F Cordia; Vladimir Spasojevic; Jeonghoon Sun; Sarah Franc; Younhee Cho
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

2.  A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.

Authors:  Geetha Thiagarajan; Andrew Semple; Jose K James; Jason K Cheung; Mohammed Shameem
Journal:  MAbs       Date:  2016-05-21       Impact factor: 5.857

3.  Nonspecific shielding of unfavorable electrostatic intramolecular interactions in the erythropoietin native-state increase conformational stability and limit non-native aggregation.

Authors:  Douglas D Banks
Journal:  Protein Sci       Date:  2015-04-11       Impact factor: 6.725

4.  Modification of the kinetic stability of immunoglobulin G by solvent additives.

Authors:  Jonas V Schaefer; Erik Sedlák; Florian Kast; Michal Nemergut; Andreas Plückthun
Journal:  MAbs       Date:  2018-04-25       Impact factor: 5.857

Review 5.  Therapeutic protein aggregation: mechanisms, design, and control.

Authors:  Christopher J Roberts
Journal:  Trends Biotechnol       Date:  2014-06-04       Impact factor: 19.536

6.  Development of a high-throughput solubility screening assay for use in antibody discovery.

Authors:  Qing Chai; James Shih; Caroline Weldon; Samantha Phan; Bryan E Jones
Journal:  MAbs       Date:  2019-03-26       Impact factor: 5.857

Review 7.  Protein aggregation and its impact on product quality.

Authors:  Christopher J Roberts
Journal:  Curr Opin Biotechnol       Date:  2014-08-28       Impact factor: 9.740

8.  Identifying protein aggregation mechanisms and quantifying aggregation rates from combined monomer depletion and continuous scattering.

Authors:  Gregory V Barnett; Michael Drenski; Vladimir Razinkov; Wayne F Reed; Christopher J Roberts
Journal:  Anal Biochem       Date:  2016-08-07       Impact factor: 3.365

Review 9.  Early implementation of QbD in biopharmaceutical development: a practical example.

Authors:  Jesús Zurdo; Andreas Arnell; Olga Obrezanova; Noel Smith; Ramón Gómez de la Cuesta; Thomas R A Gallagher; Rebecca Michael; Yvette Stallwood; Caroline Ekblad; Lars Abrahmsén; Ingmarie Höidén-Guthenberg
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

10.  Structure based descriptors for the estimation of colloidal interactions and protein aggregation propensities.

Authors:  Michael Brunsteiner; Michaela Flock; Bernd Nidetzky
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.